ERCC1 and non-small cell lung carcinoma: Moreover, miR-495 could reverse cisplatin resistance in non-small cell lung cancer by regulating the expression of the drug resistance genes ABCG2 and ERCC1 and directly targeting UBE2C 3′-UTR, affecting cells growth, invasion, and metastasis [47].